Science Corporation implants PRIMA in first Stargardt patient
Science Corporation has implanted its PRIMA vision-restoring chip in its first patient with Stargardt disease, an inherited condition that progressively damages central vision. CEO Max Hodak said the procedure took place in May at Sydney Eye Hospital in Australia as part of an ongoing trial. During rehabilitation, the patient first identified a letter and then read a word in the following session.